Concepedia

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines

Woo Sun Kwon, Sun Young Rha, Yeon Ho Choi, Jung Ok Lee, Kyu-Hyun Park, Jae Joon Jung, Tae Soo Kim, Hei‐Cheul Jeung, Hyun Cheol Chung

Pharmacogenetics and Genomics · 2006 · 52 citations · 20 references

DOIFull text

Open access

Abstract

RRM1 2464G>A polymorphism demonstrated an association with gemcitabine sensitivity, which needs functional studies with co-expressing genes and prospective clinical studies for the clinical application as a predictive bio-marker.

References

20

Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity <i>in</i> <i>vivo</i>

Sven Hoffmeyer, Oliver Burk, Oliver von Richter et al. · Proceedings of the National Academy of Sciences · 2000 · 2.4K citations

Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects

William E. Evans, Howard L. McLeod · New England Journal of Medicine · 2003 · 1.8K citations

, , +15

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

James L. Abbruzzese, Ralf Grunewald, Elizabeth A. Weeks et al. · Journal of Clinical Oncology · 1991 · 757 citations

, , +12

Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.

Volker Heinemann, Yi-Zheng Xu, Sherri Chubb et al. · Molecular Pharmacology · 1990 · 405 citations

Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

Rafael Rosell, Kathleen D. Danenberg, V. Alberola et al. · Clinical Cancer Research · 2004 · 358 citations · Full text